Clinical Trial Update: Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates the efficacy and safety of the candesartan/hydrochlorothiazide 32/25 mg combination compared with its individual components and placeb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Candesartan (candesartan)
• Candesartan/HCT 32/25 mg (candesartan/hydrochlorothiazide)
• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)

Snippet

Sponsor: AstraZeneca | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2009-06-17